GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Cirrhosis Liver/Question Prompt List (QPL) for PBC
99

Question Prompt List (QPL) for PBC

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated October 1, 2025

The Question Prompt List (QPL) for Primary Biliary Cholangitis (PBC) is a standardized tool designed to enhance physician-patient communication, improve patient engagement in care, and optimize health outcomes for individuals living with PBC. Below is a detailed explanation of the QPL, its development process, and its clinical significance:


Goal of the QPL

The primary goal of the QPL is to provide structured guidance to patients living with PBC on what questions to ask their physicians during consultations. This helps address unmet informational and therapeutic needs, empowering patients to actively participate in their care and make informed decisions.


Rationale

Patients with PBC often face challenges in knowing what information to seek during medical appointments. This lack of structured guidance can lead to gaps in understanding their condition, treatment options, and prognosis. The QPL was developed to bridge this gap by equipping patients with a carefully curated set of questions that promote shared decision-making and personalized care.


Development Process

The QPL was developed using a rigorous, evidence-based methodology through a Delphi study that involved international PBC experts and patient representatives. Below are the key steps in its creation:

  1. Participants:
  • 108 respondents from 23 countries across 4 continents, including hepatologists, researchers, and patient advocates.
  • 56.5% of participants had over 10 years of experience with PBC.
  1. Survey Design:
  • The initial survey included 43 potential questions covering nine aspects of PBC care: diagnosis, symptoms, treatment, monitoring, comorbidities, and support.
  • Questions were evaluated based on importance, with those rated as moderately/very important by >70% of participants classified as Best Candidate Questions (BCQs).
  1. Refinement:
  • Two rounds of in-person meetings were held to refine and finalize the wording and content of the QPL for clinical usability.
  1. Consensus:
  • The final QPL was unanimously approved by 19 study team members during the consensus meeting.

Final Output

The finalized QPL contains eight core patient questions deemed most likely to improve care quality, physician-patient dialogue, and shared decision-making. These questions are:

  1. Symptom Management:
  • "What are the options to manage my itching and/or fatigue?"
  • Focuses on addressing common but often underrecognized PBC symptoms.
  1. First-Line Therapy:
  • "Am I on the correct dosage of ursodeoxycholic acid (UDCA)?"
  • Highlights the importance of proper dosing and adherence to first-line therapy.
  1. Second-Line Therapy:
  • "Do I need any therapy in addition to ursodeoxycholic acid?"
  • Guides discussions on add-on treatments such as obeticholic acid or fibrates.
  1. Disease Severity:
  • "What is my risk for liver disease progression?"
  • "Do I have cirrhosis?"
  • Prompts evaluation of fibrosis, prognosis, and disease staging.
  1. Monitoring:
  • "How often do I need a liver stiffness measurement over time?"
  • Encourages regular assessment through transient elastography (VCTE) to monitor disease progression.
  1. Bone Health:
  • "Should my bone health be monitored and/or optimized?"
  • Addresses the high risk of osteoporosis and fractures in PBC patients.
  1. Information Access:
  • "Where can I receive more information and support?"
  • Ensures patients are connected with educational resources and peer-support networks.

Clinical Importance

The QPL is designed to empower patients and improve various aspects of care, including:

  • Enhanced Dialogue:

  • Facilitates open communication between patients and physicians, ensuring that critical issues are addressed during consultations.

  • Symptom Control:

  • Provides a structured way to discuss and manage debilitating symptoms like fatigue and itching.

  • Personalized Treatment Planning:

  • Helps tailor treatment regimens based on individual needs, such as adjusting UDCA dosage or considering second-line therapies.

  • Monitoring and Risk Assessment:

  • Promotes regular evaluations of liver stiffness and bone health, ensuring timely interventions and better long-term outcomes.

  • Access to Support:

  • Directs patients to reliable educational materials and peer-support groups for additional guidance and emotional support.


Limitations

While the QPL is an evidence-based tool, its wording may need adaptation to account for:

  • Language Differences:
  • Translation may be required for non-English-speaking populations.
  • Cultural Variations:
  • Questions may need to be tailored to align with cultural norms and expectations.
  • Healthcare Settings:
  • The applicability of questions may vary depending on the healthcare system in different countries.

Conclusion

The PBC QPL is a patient-centered tool that standardizes physician-patient communication, promotes shared decision-making, and addresses key aspects of care. By empowering patients to ask pertinent questions, the QPL improves care adherence, symptom management, and overall outcomes for individuals living with PBC. It represents a significant step forward in optimizing patient engagement in chronic disease management.

Related Q&A

100

Risk Factors for Portal Vein Thrombosis in Liver Cirrhosis

Portal vein thrombosis (PVT) is a significant complication in patients with liver cirrhosis (LC), as it exacerbates portal hypertension and accelerates progression toward decompensation. Risk factors for PVT...

101

Prediction of the Risk of Developing Severe Liver Disease

The CORE model, developed by researchers at Karolinska Institutet, predicts the 10-year risk of developing severe liver diseases, such as cirrhosis and liver cancer, using a simple blood...

102

Antibiotics prophylaxis in GI bleeding in Cirrhosis Liver

Antibiotic Prophylaxis in Gastrointestinal (GI) Bleeding in Cirrhosis: A Comprehensive Overview Antibiotic prophylaxis has been a cornerstone in the management of cirrhotic patients with upper gastrointestinal (GI) bleeding...

103

Ultra-early (16 years) predictive model for MASLD

The ultra-early predictive model for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) is a promising development in preventive healthcare. This model relies on identifying specific protein changes in the...

104

Hepatic recompensation in patients with decompensated cirrhosis – What is new?

Hepatic recompensation in patients with decompensated cirrhosis has emerged as a transformative concept in liver disease management, challenging the long-held belief that cirrhosis is irreversible. Recent advancements have...

105

Acute variceal bleeding in patients with cirrhosis and portal hypertension- APASL 2025

The management of acute variceal bleeding (AVB) in patients with cirrhosis and portal hypertension has been updated in the Asia-Pacific Association for the Study of the Liver (APASL)...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer